The DOI matches its Crossref record; the references it cites are not checked yet.
Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
Open accessAbstract
Background: About 50% of cutaneous melanoma (CM) harbors the activating BRAF V600 mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number of MAPK modulators have been identified, including Spry1. In this context, we have recently demonstrated that knockout of Spry1 (Spry1 KO ) in BRAF V600 -mutant CM led to cell cycle arrest and apoptosis, repressed cell proliferation in vitro, and reduced tumor growth in vivo. Despite these findings, however, the precise molecular mechanism linking Spry1 to BRAF V600 -mutant CM remains to be elucidated. Materials and methods: Immunoprecipitation coupled to mass spectrometry was employed to gain insight into Spry1 interactome. Spry1 gene was knocked-out using the CRISPR strategy in the BRAF-mutant cell lines. Transmission electron microscopy was used to assess the relationship between Spry1 expression and mitochondrial morphology. By using in vitro and in vivo models, the effects of Spry1 KO were investigated through RNA-sequencing, quantitative real-time PCR, Western blot, and immunofluorescence analyses. The Seahorse XF24 assay allowed real-time measurement of cellular metabolism in our model. Angiogenic potential was assessed through in vitro tube formation assays and in vivo CD31 staining. Results: Spry1 was mainly located in mitochondria in BRAF V600 -mutant CM cells where it interacted with key molecules involved in mitochondrial homeostasis. Spry1 loss resulted in mitochondrial shape alterations and dysfunction, which associated with increased reactive oxygen species production. In agreement, we found that nuclear hypoxia-inducible factor-1 alpha (HIF1α) protein levels were reduced in Spry1 KO clones both in vitro and in vivo along with the expression of its glycolysis related genes. Accordingly, Ingenuity Pathway Analysis identified “HIF1α Signaling” as the most significant molecular and cellular function affected by Spry1 silencing, whereas the glycolytic function was significantly impaired in Spry1 depleted BRAF V600 -mutant CM cells. In addition, our results indicated that the expression of the vascular endothelial growth factor A was down-regulated following Spry1 KO , possibly as a result of mitochondrial dysfunction. Consistently, we observed a substantial impairment of angiogenesis, as assessed by the tube formation assay in vitro and the immunofluorescence staining of CD31 in vivo. Conclusions: Altogether, these findings identify Spry1 as a potential regulator of mitochondrial homeostasis, and uncover a previously unrecognized role for Spry1 in regulating nuclear HIF1α expression and angiogenesis in BRAF V600 -mutant CM. Significance: Spry1 KO profoundly impacts on mitochondria homeostasis, while concomitantly impairing HIF1α-dependent glycolysis and reducing angiogenesis in BRAF-mutant CM cells, thus providing a potential therapeutic target to improve BRAF V600 -mutant CM treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, six of the 19 prognostic genes are non-enzymatic regulators that modulate glycolytic flux via receptor signaling or transcriptional control (16–21).”
From Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through literature research, six genes (WNT3A, VIPR1, ADRB2, SPRY1, PDGFB, and RXFP1) related to lung cancer and the regulation of glycolytic metabolic pathways were identified among the 19 genes.”
From Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 74 · Cited by 10
Metadata
- Authors
- Montico, B., Giurato, G., Guerrieri, R., Colizzi, F., Salvati, A., Nassa, G., Lamberti, J., Memoli, D., Sabatelli, P., Comelli, M., Bellazzo, A., Fejza, A., Camicia, L., Baboci, L., Dal Bo, M., Covre, A., Nyman, T. A., Weisz, A., Steffan, A., Maio, M., Sigalotti, L., Mongiat, M., Andreuzzi, E., & Fratta, E.
- Affiliations
- Centro di Riferimento Oncologico (IT)
- University of Salerno (IT)
- Istituto di Genetica Molecolare (IT)
- University of Udine (IT)
- University for Business and Technology (XK)
- University of Siena (IT)
- Oslo University Hospital (NO)
- IRCCS Materno Infantile Burlo Garofolo (IT)
- Corresponding author
- Fratta, Elisabetta
- ORCID
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-02-14
- Volume
- 44
- Issue
- 1
- Pages
- 53-53
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC11827140
- OpenAlex
- W4407578951
- Cited by
- 10
- References
- 74
- Citations by year
- 2026: 6 · 2025: 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-21)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero della Salute (GR-2018-12366312, RF-2018-12365425)
- Associazione Italiana per la Ricerca sul Cancro (IG-23068, IG-23643)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- SPRY1, BRAF V600 mutation, cutaneous melanoma, HIF-1α, glycolysis, angiogenesis, mitochondrial dysfunction, reactive oxygen species, MAPK signaling, VEGF-A, tumor hypoxia, tumor growth, cell proliferation, apoptosis, cell cycle arrest, tumor microenvironment
- MeSH terms
- Cutaneous Malignant Melanoma, Angiogenesis, Animals, Glycolysis, Humans, Melanoma, Membrane Proteins, Mutation, Neovascularization, Pathologic, Phosphoproteins, Skin Neoplasms, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma. https://app.cochat.ai/papers/10.1186/s13046-025-03289-8
- The paper
- Montico, B., Giurato, G., Guerrieri, R., Colizzi, F., Salvati, A., Nassa, G., Lamberti, J., Memoli, D., Sabatelli, P., Comelli, M., Bellazzo, A., Fejza, A., Camicia, L., Baboci, L., Dal Bo, M., Covre, A., Nyman, T. A., Weisz, A., Steffan, A., . . . Fratta, E. (2025). Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-025-03289-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.